| 2025 | FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma
| CANCER TREATMENT REVIEWS |
| 2025 | Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort
| CANCER |
| 2025 | Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2025 | The effect of nurse-led enhanced supportive care as an early primary palliative care approach for patients with advanced cancer: A randomized controlled trial
| INTERNATIONAL JOURNAL OF NURSING STUDIES |
| 2025 | Psychometric Validation of Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients
| CANCER RESEARCH AND TREATMENT |
| 2025 | Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study | LANCET ONCOLOGY |
| 2025 | Identifying Anti-cancer Effects and Exploring the Mechanism of an MPS1/TTK Inhibitor in Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2025 | Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups | CANCER LETTERS |
| 2025 | Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1-Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial
| CANCER RESEARCH AND TREATMENT |
| 2025 | First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
| ADVANCES IN THERAPY |
| 2025 | Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial
| NATURE COMMUNICATIONS |
| 2025 | Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution
| CANCER DISCOVERY |
| 2025 | Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
| ANNALS OF ONCOLOGY |
| 2025 | Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials
| CLINICAL GENITOURINARY CANCER |
| 2025 | Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
| EUROPEAN JOURNAL OF CANCER |
| 2025 | An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations
| ESMO OPEN |
| 2025 | INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2025 | Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial
| JCO PRECISION ONCOLOGY |
| 2025 | Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024
| JOURNAL OF GASTRIC CANCER |
| 2025 | Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
| CANCER RESEARCH AND TREATMENT |
| 2024 | Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
| GASTRIC CANCER |
| 2024 | Systemic Therapy of Gastric Cancer-State of the Art and Future Perspectives
| CANCERS |
| 2024 | Varlitinib and Paclitaxel for EGFR/HER2 Co-expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
| CANCER RESEARCH AND TREATMENT |
| 2024 | Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Pembrolizumab in HER2-Positive Gastric Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2024 | Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET GASTROENTEROLOGY & HEPATOLOGY |
| 2024 | Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
| EUROPEAN UROLOGY |
| 2024 | Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program
| FRONTIERS IN ONCOLOGY |
| 2024 | Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study | LANCET ONCOLOGY |
| 2024 | Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial | BMJ-BRITISH MEDICAL JOURNAL |
| 2024 | Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023
| GASTRIC CANCER |
| 2024 | Reply to B. Freidlin et al | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Исследование III фазы CLEAR у пациентов с распространенным почечно-клеточным раком: анализ в подгруппах больных, получавших ленватиниб с пембролизумабом и сунитиниб
| ONKOUROLOGIYA |
| 2024 | Pembrolizumab plus chemotherapy for advanced gastric cancer – Authors' reply | LANCET ONCOLOGY |
| 2024 | The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | FUTURE ONCOLOGY |
| 2024 | Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma | BIOORGANIC CHEMISTRY |
| 2024 | Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study | LANCET ONCOLOGY |
| 2024 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
| ESMO OPEN |
| 2024 | Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
| BMC CANCER |
| 2024 | First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
| 2024 | Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
| NATURE COMMUNICATIONS |
| 2024 | Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer | CLINICAL CHEMISTRY AND LABORATORY MEDICINE |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2023 | Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
| SCIENTIFIC REPORTS |
| 2023 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | LANCET ONCOLOGY |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
http://orcid.org/0000-0002-2512-4531
(7006023235)
